Tag: BMS

Bristol-Myers Squibb Presented Positive Clinical Results from CC-486 Study

blood
Bristol-Myers Squibb Company announced clinical results from the QUAZAR AML-001 study, evaluating investigational agent CC-486 as maintenance therapy in a broad population of patients with front-line,...

BMS Lisocabtagene Maraleucel Achieved Trial’ Endpoints

Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study. Liso-cel is an in...

BMS Blood Cancer Treatment Achieved Primary and Secondary Endpoints

bms
Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study. Liso-cel is an in...

FDA Granted Orencia Breakthrough Therapy Status

Bristol-Myers Squibb (BMS) has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its Orencia (abatacept) to prevent moderate to severe acute graft-versus-host dise...

US Competition Regulators Gave Green Light to BMS/Celgene Merger

bms
Bristol-Myers Squibb and Celgene’s merger looks set to close after US competition regulators finally gave the $74 billion deal the go-ahead. The merger has been given the go-ahead by the Federal Tr...

BMS Agreed to Transfer Rights for Daklinza to Pharmstandard

Pharmstandard JSC and Bristol-Myers Squibb (BMS) have signed agreements to transfer the rights to manufacture, sell and distribute medicinal product Daklinza (INN-Daclatasvir) in the territory of Russ...

BMS Gets EC Approval for Opdivo

bms
Bristol-Myers Squibb Company announced that the European Commission (EC) has approved Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused ...

BMS-Pfizer Alliance and Fitbit Work Together to Improve Earlier Detection of Stroke

bms
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib) with...

BMS Registered New Indication for Opdivo in Russia

Bristol-Myers Squibb Company announced that it has registered in Russia a new indication for the immuno-oncological drug Opdivo® (nivolumab), namely, as a monotherapy for common or recurrent cancer of...

BMS Announced Opdivo’s Long-Term Pooled Efficacy and Safety

bms
Bristol-Myers Squibb Company announced long-term pooled efficacy and safety results from the Phase 3 CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small ce...

BMS and BioMotiv Announce New Strategic Partnership

BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company announced a new strategic ...

FDA Granted Breakthrough Therapy Designation for Bempegaldesleukin

Nektar Therapeutics and Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-2...

New Turn in Patent Dispute Between Bristol-Myers Squibb and Natco Pharma

A patent dispute between USA-based pharma major Bristol-Myers Squibb and Indian pharma company Natco Pharma has taken a new turn with the Delhi High Court awarding interim relief to Hyderabad-based Na...

BMS Completed Divestment of Consumer Health Business to Taisho Pharmaceutical

bms
Bristol-Myers Squibb Company announced that effective July 1, 2019 it has completed its previously announced divestment of its consumer health business, UPSA, to Taisho Pharmaceutical Co., Ltd., the l...

BMS Provides Update on Celgene’s Merger

Bristol-Myers Squibb Company provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation. The Company remains actively engaged in discussions with...

BMS Announced Data from ORENCIA Phase IV Clinical Trials

Bristol-Myers Squibb Company announced data from a Phase IV mechanistic study exploring differences in the cellular and molecular mechanisms by which ORENCIA® (abatacept) and another treatment, adalim...